Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIO-RAD LABORATORIES, INC.

(BIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Posting Modest Friday Advance

07/30/2021 | 01:37pm EDT


ę MT Newswires 2021
All news about BIO-RAD LABORATORIES, INC.
08/31BIO RAD LABORATORIES : Rad to Participate in the 2021 Virtual Wells Fargo Health..
BU
08/0310X GENOMICS : After Intense Patent Litigation Bio-Rad And 10x Genomics Settle T..
AQ
07/30BIO RAD LABORATORIES : Management's Discussion and Analysis of Financial Conditi..
AQ
07/30Tranche Update on Bio-Rad Laboratories, Inc.'s Equity Buyback Plan announced ..
CI
07/30SECTOR UPDATE : Health Care Stocks Scratching Out Small Advance Just Ahead of Fr..
MT
07/30SECTOR UPDATE : Health Care Stocks Posting Modest Friday Advance
MT
07/30BIO RAD LABORATORIES : Wells Fargo Adjusts Price Target on Bio-Rad Laboratories ..
MT
07/29BIO RAD LABORATORIES : Rad Reports Second-Quarter 2021 Financial Results (Form 8..
PU
07/29BIO-RAD : Q2 Earnings Snapshot
AQ
07/29BIO RAD LABORATORIES : Q2 Adjusted Earnings More Than Double as Revenue Improves
MT
More news
Analyst Recommendations on BIO-RAD LABORATORIES, INC.
More recommendations
Financials (USD)
Sales 2021 2 845 M - -
Net income 2021 486 M - -
Net cash 2021 1 174 M - -
P/E ratio 2021 49,0x
Yield 2021 -
Capitalization 23 473 M 23 473 M -
EV / Sales 2021 7,84x
EV / Sales 2022 7,63x
Nbr of Employees 8 000
Free-Float 70,8%
Chart BIO-RAD LABORATORIES, INC.
Duration : Period :
Bio-Rad Laboratories, Inc. Technical Analysis Chart | BIO | US0905722072 | MarketScreener
Technical analysis trends BIO-RAD LABORATORIES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 788,35 $
Average target price 771,25 $
Spread / Average Target -2,17%
EPS Revisions
Managers and Directors
Norman D. Schwartz Chairman, President & Chief Executive Officer
Ilan Daskal Chief Financial Officer & Executive Vice President
Andrew J. Last Chief Operating Officer & Executive Vice President
Jeffrey L. Edwards Independent Director
Gregory K. Hinckley Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIO-RAD LABORATORIES, INC.35.24%23 473
ABBOTT LABORATORIES15.80%224 776
MEDTRONIC PLC10.72%174 552
BECTON, DICKINSON AND COMPANY4.69%75 229
HOYA CORPORATION30.10%62 323
ALIGN TECHNOLOGY, INC.34.62%56 839